Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-838 |
Synonyms | |
Therapy Description |
ABBV-838 is an antibody-drug conjugate (ADC) comprising a monoclonal CS1 antibody linked to a monomethyl auristatin E, which delivers the anti-microtubule agent to CS1-expressing cancer cells, potentially resulting in cell cycle arrest and apoptosis (PMID: 31969330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-838 | Azintuxizumab Vedotin|ABBV838|ABBV 838 | ABBV-838 is an antibody-drug conjugate (ADC) comprising a monoclonal CS1 antibody linked to a monomethyl auristatin E, which delivers the anti-microtubule agent to CS1-expressing cancer cells, potentially resulting in cell cycle arrest and apoptosis (PMID: 31969330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|